(VIANEWS) – Equus Total Return (EQS), Randgold (GOLD), BioMarin Pharmaceutical (BMRN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Equus Total Return (EQS)
139.2% sales growth and 29.21% return on equity
Equus Total Return, Inc. is a business development company (BDC) specializing in leveraged buyouts, management buyouts, corporate partnerships/joint ventures, growth and expansion capital, acquisition financing, roll-up acquisition strategies, operational turnarounds, recapitalizations of existing businesses, special situations, equity and equity-oriented securities issued by privately owned companies, debt securities including subordinate debt, debt convertible into common or preferred stock, or debt combined with warrants and common and preferred stock, and preferred equity financing. It invests in small to mid-sized companies and acts as a lead investor. It invests in technology, telecommunication, financial services, natural resource and industrial manufacturing and services. It invests in companies engaged in the alternative energy, real estate, healthcare, education, e-learning, leisure and entertainment, and foreign investment sector in the United States, China, India, and Europe. It investments include common and preferred stock, debt convertible into common or preferred stock, debt combined with warrants and options, and other rights to acquire common or preferred stock. It seeks to invest in companies between $1 million to $25 million with revenues between $5 million and $150 million with EBITDA between $2 million to $50 million. It seeks to take control and non-control equity positions. Equus Total Return, Inc. was founded in 1991 and is based in Houston, Texas with additional office in Vancouver, Canada.
Earnings Per Share
As for profitability, Equus Total Return has a trailing twelve months EPS of $0.87.
PE Ratio
Equus Total Return has a trailing twelve months price to earnings ratio of 1.48. Meaning, the purchaser of the share is investing $1.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.21%.
Sales Growth
Equus Total Return’s sales growth is 139.2% for the ongoing quarter and 139.2% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4616.7%, now sitting on 526k for the twelve trailing months.
Yearly Top and Bottom Value
Equus Total Return’s stock is valued at $1.28 at 06:22 EST, way below its 52-week high of $1.95 and higher than its 52-week low of $1.20.
2. Randgold (GOLD)
26.7% sales growth and 6.83% return on equity
Barrick Gold Corporation engages in the exploration, mine development, production, and sale of gold and copper properties in Canada and internationally. The company also explores and sells silver and energy materials. It has ownership interests in producing gold mines located in Argentina, Canada, Côte d'Ivoire, the Democratic Republic of Congo, the Dominican Republic, Mali, Tanzania, and the United States. The company also has ownership interests in producing copper mines located in Chile, Saudi Arabia, and Zambia; and various other projects located in the Americas, Asia, and Africa. Barrick Gold Corporation was founded in 1983 and is based in Toronto, Canada.
Earnings Per Share
As for profitability, Randgold has a trailing twelve months EPS of $0.72.
PE Ratio
Randgold has a trailing twelve months price to earnings ratio of 24.83. Meaning, the purchaser of the share is investing $24.83 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.83%.
Sales Growth
Randgold’s sales growth is 6.7% for the current quarter and 26.7% for the next.
3. BioMarin Pharmaceutical (BMRN)
13.8% sales growth and 4.22% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $1.06.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 80.5. Meaning, the purchaser of the share is investing $80.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.22%.
Volume
Today’s last reported volume for BioMarin Pharmaceutical is 1090850 which is 56.48% below its average volume of 2506700.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 2.47B for the twelve trailing months.
4. Paylocity Holding Corporation (PCTY)
12.1% sales growth and 20.9% return on equity
Paylocity Holding Corporation provides cloud-based payroll and human capital management software solutions for medium-sized organizations in the United States. The company offers Payroll and Tax Services solution to simplify payroll, automate processes and manage compliance requirements within one system; expense management, on demand payment, and garnishment solutions; human capital management and employee self-service solutions, document library, compliance dashboard, and HR edge; time and attendance solution, which tracks time and attendance data, eliminating the need for manual tracking of accruals and reducing administrative tasks; schedule tracking services; and time collection devices, including kiosks, time clocks, and mobile and web applications. In addition, the company offers talent management solutions comprising recruiting and onboarding, as well as learning, performance, and compensation management; employee benefits management and third-party administrative solutions; modern workforce solutions consisting of community, premium video, survey, and peer recognition; and analytics and insights solutions covering modern workforce index, data insights, and reporting. Further, it provides implementation and training, client, and tax and regulatory services. The company's clients include for-profit and non-profit organizations across industries, including business services, financial services, healthcare, manufacturing, restaurants, retail, technology, and others. It sells its products through sales representatives. The company was founded in 1997 and is headquartered in Schaumburg, Illinois.
Earnings Per Share
As for profitability, Paylocity Holding Corporation has a trailing twelve months EPS of $3.42.
PE Ratio
Paylocity Holding Corporation has a trailing twelve months price to earnings ratio of 43.69. Meaning, the purchaser of the share is investing $43.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.9%.
Volume
Today’s last reported volume for Paylocity Holding Corporation is 284047 which is 52.95% below its average volume of 603826.
Yearly Top and Bottom Value
Paylocity Holding Corporation’s stock is valued at $149.43 at 06:22 EST, way under its 52-week high of $230.52 and way above its 52-week low of $129.94.
Moving Average
Paylocity Holding Corporation’s worth is higher than its 50-day moving average of $144.17 and below its 200-day moving average of $159.71.
Sales Growth
Paylocity Holding Corporation’s sales growth is 13.6% for the current quarter and 12.1% for the next.
5. Medpace Holdings (MEDP)
11.2% sales growth and 58.85% return on equity
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Earnings Per Share
As for profitability, Medpace Holdings has a trailing twelve months EPS of $10.63.
PE Ratio
Medpace Holdings has a trailing twelve months price to earnings ratio of 35.47. Meaning, the purchaser of the share is investing $35.47 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 58.85%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 26.1% and 17.5%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.6%, now sitting on 2.03B for the twelve trailing months.
6. Host Hotels & Resorts (HST)
8.8% sales growth and 10.49% return on equity
Host Hotels & Resorts, Inc. is an S&P 500 company and is the largest lodging real estate investment trust and one of the largest owners of luxury and upper-upscale hotels. The Company currently owns 74 properties in the United States and five properties internationally totaling approximately 46,100 rooms. The Company also holds non-controlling interests in six domestic and one international joint ventures. Guided by a disciplined approach to capital allocation and aggressive asset management, the Company partners with premium brands such as Marriott®, Ritz-Carlton®, Westin®, Sheraton®, W®, St. Regis®, The Luxury Collection®, Hyatt®, Fairmont®, Hilton®, Swissôtel®, ibis® and Novotel®, as well as independent brands. For additional information, please visit the Company's website at www.hosthotels.com.
Earnings Per Share
As for profitability, Host Hotels & Resorts has a trailing twelve months EPS of $1.02.
PE Ratio
Host Hotels & Resorts has a trailing twelve months price to earnings ratio of 17.51. Meaning, the purchaser of the share is investing $17.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.49%.
7. Brinks Company (BCO)
6% sales growth and 23.33% return on equity
The Brink's Company provides secure transportation, cash management, and other security-related services in North America, Latin America, Europe, and internationally. The company offers armored vehicle transportation of valuables; automated teller machine (ATM) management services, such as cash replenishment, replenishment forecasting, cash optimization, ATM remote monitoring, service call dispatching, transaction processing, installation, and first and second line maintenance services; network infrastructure; and cash-in-transit services. It also provides transportation services for diamonds, jewelry, precious metals, securities, bank notes, currency, high-tech devices, electronics, and pharmaceuticals; vault outsourcing and money processing services; and services related to deploying and servicing intelligent safes and safe control devices, as well as cashier balancing, counterfeit detection, account consolidation, electronic reporting, check imaging, and reconciliation services. In addition, the company offers technology applications, including online cash tracking, cash inventory management, and other web-based tools. Further, it provides bill payment acceptance and processing services; prepaid cards and corporate debit cards; and security system design and installation services that include alarms, motion detectors, closed-circuit televisions, and digital video recorders, as well as access control systems comprising card and biometric readers, electronic locks, and turnstiles. Additionally, the company offers monitoring services; and security and guarding services to protect airports, offices, warehouses, stores, and public venues. It serves banks and financial institutions, retailers, government agencies, mints, jewelers, and other commercial operations. The company was formerly known as The Pittston Company and changed its name to The Brink's Company in May 2003. The Brink's Company was founded in 1859 and is headquartered in Richmond, Virginia.
Earnings Per Share
As for profitability, Brinks Company has a trailing twelve months EPS of $2.62.
PE Ratio
Brinks Company has a trailing twelve months price to earnings ratio of 40.21. Meaning, the purchaser of the share is investing $40.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.33%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 24.6% and 9.9%, respectively.
Yearly Top and Bottom Value
Brinks Company’s stock is valued at $105.34 at 06:22 EST, below its 52-week high of $107.84 and way higher than its 52-week low of $64.15.
Volume
Today’s last reported volume for Brinks Company is 210467 which is 22.24% below its average volume of 270685.
Moving Average
Brinks Company’s worth is higher than its 50-day moving average of $101.00 and way higher than its 200-day moving average of $86.30.
